Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
Delpor’s innovative Prozor technology receives support from the National Institute of Mental Health in an effort to reduce relapse in patients suffering from schizophrenia and bipolar disorder.
SAN FRANCISCO, CA, June 20, 2012 –Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced the awarding of a $340K grant from the National Institute of Mental Health for the further advancement of the company’s 3-month risperidone product (DLP-114). The product is based on Delpor’s ProzorTM technology and is expected to deliver therapeutic levels of risperidone for a period of at least 3 months in order to improve medication adherence.
“We are honored to receive this grant award and extremely grateful to the National Institute of Mental Health for believing in our vision.” said Tassos Nicolaou, President and CEO of Delpor. “We look forward to employing these new funds to further develop our risperidone program which is expected to offer tremendous treatment benefits to patients suffering from schizophrenia or bipolar disorder.”
Lack of medication adherence is one of the most frequently cited unmet needs in the treatment of schizophrenia and bipolar disorder and it is a major reason that neuroleptic drugs are not more effective in keeping people with schizophrenia out of the hospital. It is estimated that lack of medication adherence accounts for approximately 40% of all relapse. With each successive relapse, the patient’s long-term prognosis deteriorates and previous level of functioning is rarely achieved. Current long acting systems have shown some improvement, but also have certain limitations.
Tassos Nicolaou continued: “DLP-114 is expected to overcome several limitations of the current depot injections. More specifically, the system is expected to further improve medication adherence by extending the release from a couple of weeks to several months, offer full reversibility in case the patient has a treatment related adverse event, and reduce side effects by providing a consistent and superior pharmacokinetic profile.” Mr. Nicolaou concluded by saying: “This is not just about improving medication adherence. It is about addressing an important unmet medical need and improving clinical outcomes for patients suffering from a chronic and disabling brain disorder.”
About Delpor, Inc.